Assessing the Efficacy and Safety of Misoprostol Prior to Hysteroscopy in Women with Difficult Cervix: A Systematic Review and Meta-Analysis

• Published in: Journal of clinical medicine 2024-09, Vol.13 (18), p.5494
• Main Authors: Karimzadeh, Atieh, Allahqoli, Leila, Salehiniya, Hamid, Hanjani, Soheil, Namavari, Ghazal, Fazel Anvari-Yazdi, Abbas, Tahermanesh, Kobra, Alkatout, Ibrahim
• Format: Article
• Language: English
• Subjects: Bias; Biopsy; Cervix; Cervix uteri; Clinical trials; Dosage and administration; Drug therapy; Evaluation; Health aspects; Hysteroscopy; Menopause; Menstruation; Meta-analysis; Methods; Misoprostol; Patient outcomes; Performance evaluation; Physiological aspects; Postmenopausal women; Statistical analysis; Systematic Review; Vagina; Women
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13185494

Hysteroscopy has been used as both a diagnostic and therapeutic tool for intrauterine pathologies under direct visualization. However, this procedure may be associated with an increased risk of complications during entry, which can be reduced by cervical ripening before the operation. The efficacy of misoprostol in this context is influenced by factors such as estrogen levels, parity, and the mode of previous deliveries. This study aimed to assess the efficacy and safety of misoprostol in women with a challenging cervix while mitigating the influence of confounding variables. Three electronic databases, namely PubMed, Scopus, and ISI Web of Science, were searched until 14 May 2024. Randomized controlled trials focusing on postmenopausal patients, nulliparous women, and multiparous women with no prior history of vaginal delivery, undergoing hysteroscopy were included. The cervical width, time needed for cervical dilation, and the need for additional dilatation alongside the complications and adverse effects from all included studies were collected and analyzed using R (version 4.2.3). Seven studies on premenopausal women and three on postmenopausal women were included. In premenopausal women, misoprostol significantly increased cervical width compared to placebo (SMD = 2.2, 95% CI 0.9 to 3.4) and reduced the need for additional cervical dilatation (OR = 0.36, 95% CI 0.17 to 0.74). No significant difference was found in the time required for cervical dilation between misoprostol and placebo groups. In postmenopausal women, misoprostol did not significantly affect cervical width compared to placebo (SMD = -0.55, 95% CI -1.3 to 0.21). Misoprostol is beneficial for cervical dilation in premenopausal women without a prior history of vaginal delivery but less effective in postmenopausal patients. While associated with postoperative risks, it reduces hysteroscopy-related complications. Future research should address discrepancies by controlling the confounding variables like menopausal status, parity, and mode of delivery to enhance the understanding of misoprostol's effects and pinpoint the specific patient populations that would derive the greatest benefits from its use.